Abstract
Systemic lupus erythematosus is more than a heterogeneous autoimmune disease. It is in fact a syndrome of many different clinical genotypes and phenotypes. This review covers the most recently studied monoclonal antibodies and those currently being investigated. The key trials are summarized, including those for biologics on the market for two decades and those just approved for lupus less than two years ago. The focus will be on the following four: Rituximab, Abatacept, Belimumab, and Epratuzumab. It is a challenge to design the perfect trial and study patients with this disease as each has his or her own unique manifestations, biological markers, and underlying genetic background. However, as our understanding of the immune mechanisms involved in lupus increases; novel therapies will emerge that can be utilized for appropriately selected patients.
Keywords: Antibodies, biologics, lupus, monoclonal antibody, SLE, systemic lupus erythematosus, treatment.
Current Pharmaceutical Biotechnology
Title:Update on the Use of Biologics in Lupus
Volume: 15 Issue: 6
Author(s): Manisha Relan, Sahana Vishwanath, Long Shen and Julian L. Ambrus Jr
Affiliation:
Keywords: Antibodies, biologics, lupus, monoclonal antibody, SLE, systemic lupus erythematosus, treatment.
Abstract: Systemic lupus erythematosus is more than a heterogeneous autoimmune disease. It is in fact a syndrome of many different clinical genotypes and phenotypes. This review covers the most recently studied monoclonal antibodies and those currently being investigated. The key trials are summarized, including those for biologics on the market for two decades and those just approved for lupus less than two years ago. The focus will be on the following four: Rituximab, Abatacept, Belimumab, and Epratuzumab. It is a challenge to design the perfect trial and study patients with this disease as each has his or her own unique manifestations, biological markers, and underlying genetic background. However, as our understanding of the immune mechanisms involved in lupus increases; novel therapies will emerge that can be utilized for appropriately selected patients.
Export Options
About this article
Cite this article as:
Relan Manisha, Vishwanath Sahana, Shen Long and Jr L. Ambrus Julian, Update on the Use of Biologics in Lupus, Current Pharmaceutical Biotechnology 2014; 15 (6) . https://dx.doi.org/10.2174/1389201015666140804162053
DOI https://dx.doi.org/10.2174/1389201015666140804162053 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial: Current Strategies for Drug Discovery Targeting Neurological Autoimmune Diseases
Central Nervous System Agents in Medicinal Chemistry Immune Aging and Autoimmune Diseases in Children
Current Immunology Reviews (Discontinued) KIR Molecules: Recent Patents of Interest for the Diagnosis and Treatment of Several Autoimmune Diseases, Chronic Inflammation, and B-cell Malignancies
Recent Patents on DNA & Gene Sequences Vaccination and Induction of Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Defining Peptide Sequences: From Antigenicity to Immunogenicity Through Redundancy
Current Pharmacogenomics Functional Variants of the Interleukin-23 Receptor Gene in Non-Gastrointestinal Autoimmune Diseases
Current Medicinal Chemistry Role of Regulatory T Cells in Allergy: Implications for Therapeutic Strategy
Inflammation & Allergy - Drug Targets (Discontinued) Involvement of Membrane Channels in Autoimmune Disorders
Current Pharmaceutical Design Nutraceuticals and "Repurposed" Drugs of Phytochemical Origin in Prevention and Interception of Chronic Degenerative Diseases and Cancer
Current Medicinal Chemistry Nucleic Acids Modulate Autoimmunity Through Nucleic-Acid-Specific Toll-Like Receptors
Current Medicinal Chemistry Current Immune Therapies of Autoimmune Disease of the Nervous System with Special Emphasis to Multiple Sclerosis
Current Pharmaceutical Design Guar Gum and HPMC Coated Colon Targeted Delivery of 6-Mercapto-Purine
The Natural Products Journal Scorpion Toxin Polyptides as Therapeutic Agents: An Overview
Protein & Peptide Letters Therapeutic Monitoring of Immunotherapies in Autoimmune Diseases
Current Pharmaceutical Design Novel Approaches to the Therapy of Rheumatoid Arthritis based on an Understanding of Disease Mechanisms
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Neurological Involvement as the Initial Manifestation in Primary Sjögren's Syndrome - A Case Report
Current Rheumatology Reviews Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts
Current Drug Safety Recent Patents on the Treatment of Type 1 Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Restoration of the Immune Balance by Autologous Bone Marrow Transplantation in Juvenile Idiopathic Arthritis
Current Stem Cell Research & Therapy Emerging Peptide Therapeutics for Inflammatory Autoimmune Diseases
Current Pharmaceutical Design